Despite the growing number of examples of small-molecule inhibitors that disrupt protein-protein interactions (PPIs), the origin of druggability of such targets is poorly understood. To identify druggable sites in protein-protein interfaces we combine computational solvent mapping, which explores the protein surface using a variety of small "probe" molecules, with a conformer generator to account for side-chain flexibility. Applications to unliganded structures of 15 PPI target proteins show that the druggable sites comprise a cluster of binding hot spots, distinguishable from other regions of the protein due to their concave topology combined with a pattern of hydrophobic and polar functionality. This combination of properties confers on the hot spots a tendency to bind organic species possessing some polar groups decorating largely hydrophobic scaffolds. Thus, druggable sites at PPI are not simply sites that are complementary to particular organic functionality, but rather possess a general tendency to bind organic compounds with a variety of structures, including key side chains of the partner protein. Results also highlight the importance of conformational adaptivity at the binding site to allow the hot spots to expand to accommodate a ligand of drug-like dimensions. The critical components of this adaptivity are largely local, involving primarily low energy side-chain motions within 6 Å of a hot spot. The structural and physicochemical signature of druggable sites at PPI interfaces is sufficiently robust to be detectable from the structure of the unliganded protein, even when substantial conformational adaptation is required for optimal ligand binding.
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fragment-based drug discovery | ligand binding site | inhibitor design | side-chain adjustment U nderstanding the druggability of protein-protein interaction (PPI) interfaces is a major current problem in chemical biology, with substantial practical implications for the discovery of previously undescribed drugs and biological probe compounds. Reversible protein-protein interactions are involved at multiple points in virtually all biological pathways, including disease pathways where therapeutic intervention could bring widespread benefit (1, 2) . Although many PPI interfaces are biologically compelling targets for drug discovery, and a number of systems are known for which small molecules inhibit the interactions of two proteins with moderate to high potency (1-3), identifying druggable sites remains largely an unsolved problem. The surface cavities available at protein-protein interfaces to bind smallmolecule inhibitors substantially differ from those seen in traditional drug target proteins. The latter have one or two disproportionately large pockets with an average volume of 260 Å 3 , which form the binding site for their endogenous ligands in over 90% of proteins (4) (5) (6) . The accuracy of binding site identification can be further improved by accounting for additional properties such as shape, rigidity, and amino acid composition (7) . In contrast, the average volume of pockets seen at protein-protein interfaces is only 54 Å 3 , the same as the mean for all protein surface pockets (4) . The interface, on the average, includes six such small pockets (4) , and it is difficult to determine which one, if any, will be able to bind an inhibitor. In addition, the binding of a drug-sized ligand generally depends on the ability of a pocket to expand, and thus it is necessary to account for potential conformational changes (8, 9) . Molecular dynamics simulations demonstrate the substantial plasticity of the interface regions, but rarely provide the information required for the identification of specific sites and for determining their druggability (9) .
In this paper we show that the sites capable of binding drugsized ligands can be identified computationally using a fragmentbased approach, even when only unbound protein structures are available. The method is based on the observation that the binding sites of proteins generally include smaller regions called hot spots that are major contributors to the binding free energy (10) . In drug design applications, such hot spots can be identified by screening for the binding of fragment-sized organic molecules (11, 12) . Because the binding of small compounds is weak, experimental screening of fragment libraries requires special techniques. Examples include nuclear magnetic resonance methods such as SAR (structure-activity relationship) by NMR (11) , and the MSCS (multiple solvent crystal structures) approach (12) based on X-ray crystallography. The results of experimental fragment screens confirm that the hot spots of proteins are characterized by their ability to bind a variety of small molecules and that the number of different "probe" molecules observed to bind to a particular site predicts the potential importance of the site and is predictive of overall druggability (11) (12) (13) (14) .
Computational solvent mapping was developed as a virtual analogue of the SAR by NMR and MSCS methods (13) . Mapping places molecular probes-small organic molecules that vary in size and shape-on a dense grid around the protein, finds favorable positions using empirical free energy functions, clusters the conformations, and ranks the clusters on the basis of the average free energy. The regions that bind several probe clusters are called consensus sites, and the one binding the largest number of probe clusters is considered the main hot spot (13) (14) (15) . Based on a variety of proteins using 16 different types of probes, we have shown that the main hot spot in all druggable targets binds at least 16 probe clusters and, together with nearby hot spots, predicts the site that can potentially bind drug-size ligands (13) (14) (15) . Although solvent mapping shows formal similarity to earlier computational methods (16, 17) , it correctly shows that small organic molecules bind and cluster only at a few sites on a protein (12) .
Here we describe a four-step algorithm, which extends computational solvent mapping to PPI targets. The basic idea of the method is to identify small pockets by an initial mapping and then identify energetically accessible conformational adaptations of nearby side chains to accommodate drug-size molecules. Accordingly, the method finds the main hot spot, uses a set of rules to select the potentially important side chains nearby, generates their energetically accessible conformers, maps all alternative structures (18) , and selects the one with the highest number of probe clusters in the binding site. Table 1 lists the rank of the consensus sites, and in parentheses the number of probe clusters, from the mapping of 15 PPI targets. The analysis of the first six targets, discussed by Wells and McClendon (1), will be described in more details (see also Table S1 ). The next six proteins (XIAP Bir3 through survivin) are PPI targets from the landmark paper on druggability indices by Fesik and co-workers (11), whereas druggability information on HIV integrase (19) , CD40L (20) , and B-cell activating factor (BAFF) (21) is based on original reports. The mapping of the last nine proteins is described in SI Appendix, which also provides results for 28 additional targets. Both ligand-free and (if available) ligand-bound structures were mapped, the latter after removing the bound ligand. We denote the largest, second largest, and further consensus sites of each protein as CS1, CS2, CS3, and so on, where the size of each site is defined in terms of the number of probe clusters it binds (14, 15) . In the figures the inhibitor is always superimposed on the mapping results for reference, but we emphasize that all ligands are removed prior to mapping, and we rely only on the protein structure. After validating the method, we studied the feasibility of disrupting the eIF4E/eIF4G complex, a promising PPI target for anticancer therapy (22) (23) (24) .
Results
Hot Spots and Druggability Assessment for Six Well-Studied PPI Targets. Interleukin-2. Interleukin 2 (IL-2) is an immunoregulatory cytokine that stimulates normal and pathogenic T cells and contributes to rejection of tissue grafts (25) . A number of small molecules (e.g., compound 1 in Fig. S1 ) inhibit the interactions of IL-2 with IL-2Rα (26) (27) (28) . The binding site for these compounds includes a largely polar and rigid pocket, and a highly adaptive hydrophobic region (27) . We mapped both the unliganded and ligand-bound IL-2 structures and in each case found the hot spots that were also identified experimentally at the two ends of the inhibitor (Fig. 1A and Table S1 ). Throughout the paper, the results of mapping two different structures of the same protein will be compared in terms of mapping fingerprints, i.e., the percentages of nonbonded interactions between the probes and each amino acid residue of the protein. Fig. 1A also shows the mapping fingerprints for the two Il-2 structures, with the stars indicating the residues that interact with the inhibitor (27) . Although there are differences in the distributions of probe-residue contacts, apart from residue T41 mapping finds the same residues in both unliganded and ligand-bound structures, in contrast to the prevailing view that the ligand binding site in IL-2 is not predictable based on the unbound structure (1, 9, 27) . We note that no low energy alternative side-chain conformers were found for the unbound IL-2 (Table 1) .
B-cell lymphoma-extra large (Bcl-xL). Bcl-xL is overexpressed in many cancers and consequently has been actively pursued as a target for small-molecule drug discovery (1, 2, 29, 30) . Abbott Laboratories has developed a set of Bcl-xL inhibitors, among them ABT-737 (compound 2 in Fig. S1 ) (31) . Mapping the unliganded Bcl-xL structure yielded only one large hot spot (Fig. S2A) . Assessing the energetically accessible conformations of the side chains within the 6-Å neighborhood of this initial hot spot identifies several mobile residues (Table S3 ). The conformer that gave the strongest mapping result involved switching to the second lowest energy conformers for the side chains of R100 and Y101 (Table S4) . These side-chain motions opened up a pocket that bound the same number of probe clusters as the inhibitorbound structure (70 in both cases). The side-chain rearrangements that optimized the computational mapping results agree well with the conformational changes that were observed experimentally to occur upon ligand binding (Fig. S2B) . Mapping of this conformer yielded four key hot spots (Fig. 1B and Table S1 ), in good agreement with the results of mapping the ligand-bound Bcl-xL structure and overlapping well with the binding site for ABT-737 as established from the cocrystal structure of this compound with Bcl-xL. Fig. 1B also shows the mapping fingerprints (cyan, 20) is in the rigid hydrophilic pocket close to the site that binds the guanido group of compound 1, CS4 (salmon, 10) is at the adaptive hydrophobic pocket overlapping with the dichlorophenyl moiety. The number in parentheses following the color code indicates the number of probe clusters. Only the protein is used in the mapping; the inhibitor is shown for reference. CS1 is in the IL-2/IL-2Rα interface, and CS4 is close to it. We note that CS2 (17 probe clusters) and the small hot spot CS8 (4 clusters) are in the IL-2/IL-2Rβ interface, which makes this second interface also druggable. (Middle) IL-2 structure from the cocrystal with compound 1 (PDB ID code 1pw6). CS1 (cyan, 16) is now in the adaptive hydrophobic pocket, and CS3 (salmon, 13) identifies the rigid polar pocket. (Lower) Mapping fingerprints for IL-2, i.e., the percentages of nonbonded interactions between the probes and each amino acid residue. Green, unbound; blue, bound. Stars indicate residues interacting with compound 1 (Fig. S1 ). Mouse double minute protein 2 (MDM2). The human version of the MDM2 influences transcription by binding to the tumor suppressor p53 (32, 33) . Roche reported a series of cis-imidazoline analog inhibitors termed Nutlins (e.g., compound 3 in Fig. S1 ) (34) . We mapped the 24 NMR structures of unliganded MDM2 (Table S7) . Results for the structure binding the largest number of probe clusters show that the two main hot spots overlap the binding location of compound 3 ( Fig. 2A) . The same sites are identified by mapping the structure of MDM2, cocrystallized with compound 3 ( Fig. 2A and Table S1 ). The results show that mapping an ensemble of conformations and selecting a structure with the highest number of probe clusters correctly identify the druggable site. Fig. 2A also shows the mapping fingerprints for the unbound and bound MDM2 structures, as well as the interactions with compound 3 (indicated by stars).
Human papilloma virus (HPV)-11 E2. The interaction between the HPV transcription factor E2 and viral helicase E1 is an important PPI target (1, 35, 36) . A series of small molecules have been reported that bind to E2 and inhibit its interaction with E1 (36) . Although two inhibitor molecules were observed in the binding pocket, it was suggested that the interaction with the second molecule is probably a crystallization artifact (36) . Results of mapping the unliganded HPV-11 E2 are shown in Fig. S3 . Application of the alternative side-chain algorithm in the neighborhood of this hot spot indicates a number of potentially mobile side chains (Table S5 ). The conformer that gave the strongest mapping results involved alternative conformers for four side chains, expanding the pocket in this region and improving the correlation with the mapping results for the ligand-bound structure (Table S6) . Fig. 2B and Table S1 show results for both the adjusted unbound structure and the structure bound to compound 4. In both cases a large consensus site (CS1 or CS2) identifies the pocket that binds the indandione moiety of the higher affinity inhibitor. Mapping also finds two additional hot spots, one overlapping with the second inhibitor molecule, and the other at a site that in the X-ray structure binds isobutyric acid, a component of the crystallization medium. As shown in Fig. 2B , each inhibitor molecule binds only to a single hot spot. The parts of the ligands that do not interact with hot spot residues are unlikely to substantially contribute to the binding free energy, suggesting that better lead compounds might be found that bridge the two main hot spots.
ZipA. The ZipA/FtsZ interaction has been considered as a potential target for antibacterial agents (1, 37) . Mapping of both unliganded and ligand-bound ZipA structures yielded a large hot spot (CS1), but it is not in the ZipA/FtsZ interface ( Fig. 3 A  and B) . In the interface region we find only three weak hot spots, each binding less than 10 probe clusters. All side chains in the ligand-free X-ray structure within 6 Å of the initial hot spots turned out to be stationary. Hot spots that bind fewer than 16 probe clusters do not contribute significantly to the binding free energy, and hence we predict that the ZipA/FtsZ interface is not a druggable target. In fact, efforts to identify small molecular PPI inhibitors for this system, including high throughput screening of 250,000 compounds, resulted only in weak inhibitors, with the best inhibitor (compound 5 in Fig. S1 ) having an IC50 value of approximately 1 mM (38) (39) (40) .
Tumor necrosis factor α (TNFα). Monoclonal antibodies have validated the trimeric cytokine TNFα as a high-value drug target in multiple inflammatory and immune disorders. Despite extensive efforts, no synthetic small-molecule inhibitors have been reported that bind TNFα and disrupt the interactions between the homotrimer and its receptor TNFR1 (2) . Mapping the unliganded TNFα trimer gave the unexpected result that all major consensus sites occurred in the interior of the protein among the three subunits (Fig. 3B) . The only consensus site in the TNFα-TNFR1 interface is CS7 with five probe clusters between the Y87 and Q125 side chains (Table S1 ). This finding agrees with the fact that the regions near Y87 have been identified as the principal surface binding site in an experimental fragment screen of TNFα (41) . However, the small number of probe clusters leads to categorization of the TNFα-TNFR1 interaction as not druggable, which is consistent with the failure of extensive efforts by multiple groups to identify small-molecule antagonists of TNFR binding. However, the mapping results show that the interior of the TNFα trimer has high binding affinity for the small molecules used as probes, which suggests that a suitable larger molecule might disrupt the constitutive trimer interface. Indeed, He and co-workers (41) developed SP307 (compound 6 in Fig. S1 ), which inhibited TNFα activity by displacing one of the TNFα subunits. To determine whether mapping could correctly characterize this unusual binding site, we mapped the A and B chains of TNFα, obtained by removing chain C from the trimeric structure. Once the structure becomes open with two subunits only, the largest consensus site CS1 shifts to the outside pocket near Y87, but the other consensus sites remain in the interface and coincide closely with the observed binding site of inhibitor 6 (Fig. 3B ). The agreement is further improved when mapping the inhibitor-bound TNFα dimer (Table S1 and Fig. S4 ).
Disrupting the eIF4E/eIF4G Complex. EIF4E is a eukaryotic translation initiation factor involved in directing ribosomes to the cap structure of mRNAs and is frequently overexpressed in human cancers (22) . Assembly of the eIF4E/eIF4G complex has a central role in translation initiation, and inhibition of this interaction has tumor-suppressor activity (22) . The small molecule 4EGI-1 (compound 7 in Fig. 4A ) and an analogue are the only known small inhibitors of the eIF4E/eIF4G interaction (K D ∼ 25 and 16 μM, respectively). Although no eIF4E structure is available with bound inhibitor, line broadening observed by NMR indicates that residues H37, V69, L131, and I138 on eIF4E interact with 4EGI-1 (23) . Because the inhibitor 4EGI-1 binds to eIF4E but does not compete with mRNA binding, we blocked the mRNA cap binding site prior to mapping. Mapping both the unbound eIF4E and the structure from the complex eIF4E/4E-BP1 revealed that the main hot spots CS1 through CS4 form an elongated site, which could support small-molecule interactions (Fig. 4) . We used this information to place the inhibitor 4EGI-1 using an algorithm that scores docked ligand poses based on the degree of overlap between the compound and the consensus sites (see Methods).
The results suggest that the bound inhibitor occupies only CS1 and part of CS3 (Fig. 4C ). This agrees with the published NMR line broadening (23), showing that the inhibitor interacts with residues V69, L131, and I138 within CS1 and CS3. The proximity of the hot spots to the residues with line broadening provides strong support that mapping has found the correct location for inhibitor binding.
To identify eIF4E/eIF4G inhibitors, a collection of approximately 218,000 compounds was screened using a time-resolved fluorescence resonance energy transfer assay (24) . Among a number of hits was the compound 4E1RCat (compound 8 in Fig. 4A ; PubChem ID code 16195554). Additional tests showed that 4E1RCat inhibited the eIF4E:eIF4G interaction with IC 50 ¼ 4 μM (24). The probable binding mode of 4E1RCat was determined by the same computational method we used to identify the binding mode of 4EGI-1. Fig. 4C shows that 4E1RCat occupies CS1 and part of CS3, but unlike 4EGI-1 additionally reaches into CS4, which may explain its somewhat higher affinity compared to 4EGI-1.
Discussion
The results of this paper show that based on mapping a target protein using 16 different types of probe molecules, a druggable site comprises a main hot spot binding at least 16 probe clusters in the protein-protein interface, and one or two additional hot spots nearby, within reach of a drug-sized molecule. The hot spots are distinguishable from other regions of the protein surface due to their concave topology combined with a mosaic-like pattern of hydrophobic and polar functionality (13) . This combination of properties confers on the hot spots a tendency to bind drug-like organic species possessing some polar functionality decorating a largely hydrophobic scaffold. Thus, druggable sites at PPI are not simply sites that are complementary to particular organic functionality, but rather possess a general tendency to bind organic compounds with a variety of structures. This property of hot spots accounts for their identification as consensus sites by computational solvent mapping, as well as for the experimental observation that fragment hit rate is significantly predictive of the overall prospects for identifying a high affinity drug-like ligand (11) . Our results additionally highlight the importance of conformational adaptivity at the binding site to allow hot spots to expand to accommodate a ligand of drug-like dimensions. Moreover, we show that the critical components of this adaptivity are largely local, involving primarily low energy side-chain motions within 6 Å of a hot spot. Most importantly, we show that the structural and physicochemical signature of druggable sites at PPI interfaces is sufficiently robust to be detectable from the structure of the unliganded protein, even when substantial conformational adaptation is required for optimal ligand binding. This information could potentially allow those PPI targets most likely to be druggable to be identified from structural data alone, without expanding resources on exploratory lead finding efforts against intractable targets.
The tendency of hot spots to bind many different compounds suggests that in the protein-protein complex such sites strongly interact with some residues of the partner protein. Indeed, it has been observed that the hot spot residues of protein-protein interactions generally either protrude or are located in tightly complemented pockets that become filled upon binding (42) . Finding small molecular inhibitors has a better chance if the hot spots cluster; e.g., the protruding residues are on a short peptide fragment of the partner protein. Among the proteins discussed, Bcl-xL, MDM2, ZipA, and eIF4E have been cocrystallized with such peptide fragments. The peptide-bound structures are very useful for ligand design, because the peptides and the small molecular inhibitors bind to the same sites, in good agreement with the observed generic binding tendencies. We mapped the peptide-bound structures (obviously after removing the peptide) and found that the relative ranking of the hot spots between peptide-bound and ligand-bound structures is completely conserved (Figs. S5 A-C) . However, in this paper we focused on the conservation of druggable sites between unbound and ligand-bound proteins and hence did not utilize information from the peptidebound structures.
Methods
Computational Solvent Mapping. Protein structures were downloaded from the Protein Data Bank (43) . All ligand and bound water molecules were removed. Mapping was performed using the FTMAP algorithm (15) through its online server (http://ftmap.bu.edu). FTMAP scans the entire surface of the protein with a library of 16 small organic probe molecules, with varying hydrophobicity and hydrogen bonding capability (see SI Methods). For each probe, six bound probe clusters with the lowest mean interaction energies are retained. The clusters from the different probe types are then clustered into CSs, which define hot spots where multiple probes congregate with high affinity. The CSs are ranked on the basis of the number of probe clusters they incorporate, with the largest CSs representing the most important sites.
Accounting for Side-Chain Flexibility when Mapping PPI Targets. The algorithm consists of four main steps as follows:
Step 1: Initial mapping. The unbound protein is mapped to find the largest consensus site.
Step 2: Residue selection. We consider the solvent accessible residues within 6 Å from the center of any cluster in the consensus site and select those that (i) have at least 75% of the maximum hydrophobicity value calculated for all surface residues and (ii) are located in a cavity. For (ii), we calculate a cavity measure, defined in ref. 15 , for all residues, and retain only those that exhibit 60% or more of the maximum value.
Step 3: Generating low-energy conformers for selected side chains. The conformers of the selected side chains are explored one side chain at a time by multistart energy minimization, performed in the absence of the partner protein. Only the atoms of the selected side chain are allowed to move during the minimization. The conformers from a backbone-dependent rotamer library (44) are used as initial states in the minimizations. The final frames of minimization trajectories are clustered based on the positions of their end groups using a 1-Å clustering radius. For each cluster a probability is defined by summing the probabilities of the original rotamers that converge to the particular cluster. For each cluster we also calculate the Boltzmann average energy of its members. A side chain is considered movable if it has multiple low energy and/or highly populated clusters, and the centers of the low-energy populated clusters plus the unbound state define its potential confor- mers. Otherwise a side chain is considered stationary, and its conformation seen in the unbound structure is retained.
Step 4: Selecting the structure with the largest pocket. Alternative protein structures are generated by combining all conformers of movable side chains. The alternative structures are mapped. For assessing druggability we select the structure that has the highest number of probe clusters within the 6-Å vicinity of the main consensus site.
The results of mapping two different structures of a protein are compared in terms of mapping fingerprints, i.e., the percentages of the nonbonded interactions between the probes and each amino acid residue of the protein. A high correlation coefficient between two fingerprints indicates similar mapping results and thus similar hot spots and binding sites. Table S2 shows the results of applying the algorithm to the unbound structures of 15 well-studied drug targets (45) . We note that one can account for protein flexibility without generating alternative conformations if multiple protein structures are available as in the case of NMR structures (see Table S7 ). The algorithm was also applied to 22 additional targets (see Tables S8 and S9 ), including 9 additional PPI targets also shown in Table 1 .
Docking of eIF4E Inhibitors. Based on the mapping results, a box with 4-Å padding was created around the putative binding site. The docking was carried out using the standard settings of AutoDock Vina 1.1.0 (46), and the 10 lowest energy binding modes were retained for each ligand. The selection of the most likely pose was based on the atom densities calculated from the mapping results. We considered each retained pose separately, for each atom summed the atomic densities on the grid points within a 1-Å radius, and then added these values for all atoms. The poses were ranked on the basis of this overlap measure, and the pose with the best overlap was selected. The basic ideas of extending computational solvent mapping to PPI targets is mapping a set of alternative protein structures in order to identify the one which binds the highest number of probe clusters, and thus has the largest pocket. The resulting structure provides the best candidate to bind drug sized ligands, and hence used for assessing druggability. Alternative protein structures may be available (e.g., models from solution NMR data or multiple X-tray structures) or can be generated by computational methods. One obvious choice is molecular dynamics (MD), and MD simulations have been used with success prior to mapping (4, 5) . However, we believe that the algorithm based on generating low energy conformers for the side chains in the vicinity of the initial hot spot by multi-start minimization as described in this paper offers a more efficient approach. The efficiency is due to the observation that the mapping of the ligand-free protein structure provides sufficient information to restrict considerations to surface side chains within the 6 Å neighborhood of an initial hot spot that also satisfy two other criteria. First, we consider only residues that have at least 75% of the maximum hydrophobicity value calculated for all surface residues using a hydrophobicity measure introduced in (6).
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Second, we restrict consideration to residues that are located in a cavity based on the cavity criterion used in the FTMAP program (1). These conditions are generally satisfied only by a few side chains, and application of the multi-start minimization shows that in most cases even fewer side chains are "movable", i.e., have multiple low energy and/or highly populated conformers. For proteins with a single movable side chain we map all structures defined by its conformers. For proteins with several movable side chains we consider all combinations of conformers for the movable side chains, and map the resulting structures. Once all structures have been mapped we select the side chain conformations that yield the highest number of probe clusters within the 6 Å vicinity of the consensus site from the original mapping.
In this Supporting Information we first provide additional information on the 6 PPI targets that are discussed both in the review by Wells and McClendon (7) and in our main text (Table S1 ). This includes the results of mapping both the ligand-free (after side chain adjustment) and the ligand-bound protein structures, the latter after removing the bound ligand. Since Table S1 shows the location and size of the major hot spots in both ligand-free and ligand-bound structures, it demonstrates the structural conservation of the hot spots in the protein-protein interface. Second, to further validate both the side chain adjustment algorithm and our condition for druggability, we apply the algorithm to 15 traditional drug target proteins (8) with both unbound and ligand-bound structures available (Table S2) . Third, we proceed to detailed analysis of some of the PPI targets. In particular, Bcl-xL and HPV-11 E2 have movable side chains, and the application of the algorithm to these two proteins is described in more details (Tables S3 through S6 ). Another interesting application is to MDM2, for which an ensemble of alternative protein conformations is provided by solution NMR (9), shown in Table S7 . Fourth, we apply the analysis to a number of further targets, mostly selected from Table 1 of the landmark druggability paper by Fesik and co-workers (10), resulting in Tables S8 and S9 . The strength of this additional set is that 11 of the 24 targets are considered not druggable, as suggested by the lack of success in identifying high affinity ligands. The set includes 9 PPI targets that are also shown in Table 1 . The analysis of the additional targets (both traditional and PPI) further demonstrates that the method can correctly distinguish between druggable and non-druggable proteins.
Validation: Application to traditional drug targets. Table S2 lists 15 drug target proteins from the Astex non-native data set (8) . We restricted considerations to proteins with both unbound and ligand-bound structures available, and preferably selected the ones that exhibited limited backbone motion. For these targets, the extent of side chain flexibility evident via comparison of the bound and apo structures ranged from little to large movements. For each target we mapped both the apo and the reference bound structures. All water molecules, ligands, cofactors, and metals, with the exception of the heme cofactors in reference structures 1p2y and 1mmv, were removed from the structure prior to mapping and prior to running the side chain algorithm. Table S2 shows the number of probe clusters in the binding site, both from the initial mapping of the unbound protein, and from the mapping of the resulting structure with the selected side chains adjusted.
For the latter we also list the individual consensus sites (and the number probe clusters included) in the binding site. Both mapping results are evaluated in terms of the mapping fingerprints, i.e., the percentages of nonbonded interactions between the probes and each amino acid residue of the protein. Table S2 compares both the initial and final fingerprints to that of the ligand-bound structure by calculating the correlation coefficients. According to these results, selecting side chain conformers that increase the number of probe clusters in the binding site always moves the mapping results toward those for the bound structure, increasing the correlation coefficient. Note that no movable side chains are found for 8 of the 15 targets. The last column of Table S2 lists the side chains whose conformation has been altered for the other 8 targets.
In addition to demonstrating that our side chain adjustment algorithm, Table S2 further demonstrates the condition for druggability. All targets in the Table S2 have known high affinity ligands (either K D < 300 nM or IC50 < 300 nM), apart from cytochrome P450cam, for which the best reported binder is camphor with K D = 1.9 µM (11). As shown in Table S2 , cytochrome P450cam does not strictly satisfy our druggability condition:
although it has a strong hot spot overlapping the small camphor binding site, there are no other consensus sites in the vicinity. According to our experience, targets with a single isolated hot spot are not druggable in the practical terms of finding actual drug-like compounds, although high affinity ligands may exist.
Application to Bcl-xL. Mapping the unliganded Bcl-xL structure (PDB code 1r2d) yields only one large hot spot shown in Fig. S2A . Table S3 lists the surface side chains within the 6 Å neighborhood of this hot spot that also satisfy the other two criteria, i.e., have at least 75% of the maximum hydrophobicity value calculated for all surface residues; and are located in a cavity. Table S3 also shows the results of generating low energy conformers for these side chains by the multi-start minimization as described in the methods. F97 has two high probability conformers, but the second has much higher energy and hence this side chain is considered stationary, with its conformer 1 close to both unbound and bound states. For F105 the analysis finds a single populated state. Therefore the F105 side chain is considered stationary, although the retained conformation is closer to the unbound than to the bound state. For V141 the first conformer is substantially more populated than the second. Thus, the V141 side chain is also considered stationary, and its sole retained conformer is close to both unbound and bound states. R100 has many conformational states with non-negligible probability, but in Table S3 we show only conformers 1 and 2 that have substantially lower energy than the others, and we retain both conformers for mapping. For Y101 the second state has higher energy, but also substantially higher probability, than the first state, and thus we consider two potential states also for Y101. Table S4 shows the mapping results for the resulting 4 structures and for the protein bound to ABT-737. There are 44 probe clusters in the interface when using the first conformers (that are very close to the unbound structures) for both side chains, and the number increases to 70 as we switch to the second conformer for both R100 and Y101.
As shown in Fig. S2B , selecting these conformers both side chains move toward their bound conformations.
Although the RMSD between this predicted and the bound R100 conformers is 2.08 Å, the mapping results become very similar to those obtained for the bound Bcl-xL structure (see Fig. 1B ). As shown in Table S4 , this conformation yields the same number (70) of probe clusters as the inhibitor-bound structure. We use the mapping fingerprints, i.e., the number of nonbonded interactions between the probes and each Bcl-xL residue, to measure the improvements in the quality of the mapping results when switching to the second conformers for R100 and Y101, The fingerprint for each structure is compared to the fingerprint from mapping the inhibitorbound structure, used as the "gold" standard, by calculating the correlation coefficient of the two vectors. The correlation coefficient increases from 0.51 to 0.92 as we switch to conformer 2 of both R100 and Y101 (Table   S4 ).
The lower panel of Fig. 1B shows the excellent agreement between the results of mapping the adjusted unbound and the inhibitor-bound structures. We note that this agreement is much better than the one we have obtained for the unbound and bound structures of IL-2, shown in the lower panel of Fig 1A. As shown, adjusting the conformation of two side chains in Bcl-xL we increased the size of a pre-existing pocket, increasing the number of probe clusters from 44 to 70, and this improved the agreement with the bound structure. In contrast, the unbound structure of IL-2 binds slightly more (30) probe clusters than the bound structure, which binds only 29 (see Table S1 ). Therefore, we mapped the unbound protein rather than any alternative structure, and although this yielded correct assessment of druggability, the probe-protein interactions described by mapping fingerprints differed more than for Bcl-xL.
Application to MDM2. The application of mapping to MDM2 is particularly interesting because no X-ray structure of the non-liganded protein is available, and hence the analysis was based on solution NMR structures of apo-MDM2 (PDB code 1z1m). The 24 NMR structures show considerable dynamics, and comparison to the inhibitor-bound X-ray structure reveals substantial conformational changes that accompany binding of p53, suggesting that p53 effects displacement of an N-terminal segment of apo-MDM2 that occludes access to the shallow end of the p53-binding cleft. We show that in spite of these conformational changes, the ensemble of NMR structures of the ligand-free MDM2 provides the structural information for the assessment of druggability and for the identification of the druggable site. Table S7 shows the number of probe clusters for the 24 NMR models of the unliganded MDM2, which varies between 9 and 42. Selecting any of the three models with 42 probe clusters yields a correlation coefficient of at least 0.65 with the mapping fingerprint of the ligand-bound structure. We have actually selected Model 4, which has the lowest correlation coefficient of 0.65 among the three structures. Nevertheless, as shown in Table S1 and Fig 2A, the two main hot spots found for this structure overlap the binding location of the inhibitor.
Application to further targets. Druggability (or the lack of it) has been reliably established only for a very limited number of PPIs. Therefore we also mapped the drug target proteins, considered as training set in the landmark paper on druggability indices by Fesik and co-workers (10). Although mapping results for drug target proteins are given in our Table S2 , the difference is that Fesik's set includes both druggable targets, defined as having a high affinity ligand (with K D <300 nM), and non-druggable targets for which no high affinity ligands have been identified in spite of extensive screening campaigns. Table S1 by Hajduk et al (10) lists 23 proteins.
After removing PAK4, for which no druggability information was given, and two proteins (AK and FPB) with no unbound structures available, the Fesik paper (10) provides 21 targets (including both the catalytic and the non-catalytic sites for PTP 1B). The proteins include Bcl-xL and MDM2 that we have already studied. We added three more PPI targets on which we had druggability information: one druggable (HIV integrase) and two non-druggable (CD40L and BAFF), resulting in 24 targets of which 13 are druggable and 11 are nondruggable. Among these 24 proteins 11 are PPI targets that are also listed in Table 1 .
Mapping results for the druggable targets, as defined by Hajduk et al. (10) , are shown in Table S8 , which lists the unbound structures we have mapped, and the bound structures we have used as references to identify the binding sites studied by Hajduk et al. (10) . We follow the original paper and indicate if the site to be studied binds a peptide, in most cases actually a peptide fragment of a partner protein. We note that Hajduk et al. (10) frequently provide only the PDB ID of the bound structure or no PDB ID at all (structures may not have been deposited in 2005), and hence in many cases we had to find an appropriate unbound structure. Table S8 lists the consensus sites located at the binding site (with the number of probe clusters indicated in parenthesis) as obtained by the initial mapping, and our conclusion on druggability. The last two columns show the results of adjusting the side chains in the neighborhood of the initial hot spots. We note that NMR rather than X-ray structures were available for 4 targets, and these were treated as described for MDM2, i.e., all models in the PDB file were mapped, and the one with the highest number of probe clusters was selected for determining druggability. Ligand-free X-ray structures were available for 5 PPI targets. Adjusting the side chains in the vicinity of the initial hot spots increased the number of bound probe clusters for 3 of these, Bcl-xL, Bir3, and the stromelysin catalytic domain (Table S8 ).
Mapping supports the observed druggability of all 13 druggable targets in Table S8 . The only uncertain case is the catalytic pTyr binding site of PPT 1B. Due to the large conformational change, for this protein we mapped both an open conformation (3a5j) and a closed conformation (1pa1). As shown in Table S8 , in the open conformation the binding site has a single strong consensus site. Although this would suggest that the target is most likely not druggable, in the closed conformation there is a second consensus site nearby, and therefore the protein satisfies the condition for druggability. However, the second site is very weak, ranked 9 th with 4 probe clusters. Although PTP 1B has many high affinity inhibitors (12), it is well documented that the highly cationic nature of the active site coupled with the lack of any adjacent and at least partially hydrophobic site makes the development of a drug very difficult if at all possible (13, 14) . We note that for HIV integrase, a longstanding PPI target, we find a druggable site in the interface with the LEDGF/p75 protein, and recently inhibitors disrupting this interaction have been reported, with IC 50 values as low as 580 nM (15) . Table S9 shows our mapping results for the additional targets considered not druggable. Our analysis clearly
shows that the first 8 of the 11 targets are not druggable, and this is supported by the lack of high affinity ligands. CD40L and BAFF have been the targets of unsuccessful HTS campaigns (16, 17) . For the Bir3 domain of survivin the best inhibitor targeting the Smac-peptide binding site has K D =130 µM (18, 19) . To avoid confusion we note that the mapping finds a druggable site on survivin with the consensus sites 1(24), 3(16), and 6(5) (not shown in Table S9 ), but this site is at the dimerization interface distinct from the targeted Smac/diablo peptide binding site. The novel site at the dimer interface binds inhibitors with nanomolar affinity (19) , in agreement with the prediction based on our mapping results. For the N-terminal RNA-binding domain of the SARS CoV nucleocapsid protein, the best reported ligand binding to the same face as RNA has the affinity of K D ∼1 mM (20) . The human papillomavirus type 6 E2 protein (E2-31) has only very weak hot spots in the interface with DNA, and no high affinity ligand (21) . Note that after adjusting the conformation of a single side chain, the binding site of HI-0065 has two hot spots with 14 and 5 probe clusters, relatively close to the 16 probe cluster threshold required for druggability. So far the best compounds that bind to HI-0065 from
Haemophilus influenza have a K D ∼10 µM (22) . The last among the 8 non-druggable targets is the non-catalytic pTyr binding site of PTP 1B, which is known to be very weak (12, 13) , in agreement with our mapping results.
According to our druggability condition, the IP3 binding site of Akt-PH (Akt-derived pleckstrin homology domain) is not druggable, but with consensus sites 3(14) and 4(10) it is a borderline case. Although this target was not considered druggable by Hajduk et al. (10) , it was recently discovered that the active metabolite of triciribine, TCN-P, binds Akt-PH with K D = 690 nM in the vicinity of the PIP3-binding pocket (23) , in agreement with our prediction that this target is borderline druggable. The last three targets in Table S9, possible that at some point higher affinity ligands will be found for these three targets, we note that the binding sites of CMPK and ErmAM are more polar than those of the druggable targets in Tables S1, S2 , and S8. Thus, it may be necessary to add some polarity constraints to form a more stringent general condition for druggability. However, since the binding sites of the PPI targets are always in the more hydrophobic category, this additional condition would not affect the results of the present paper. We also note that for PPI targets small compounds with low micromolar affinity are frequently considered hopeful starting points for further analysis, partially because many drug candidates have larger molecular weight than traditional drugs do. A well-known example is ABT-737, a Bcl-xL inhibitor in clinical trials. Thus, although our druggability condition is less stringent than the one defined by Hajduk et al. (10), it may be more appropriate in applications to PPI targets, because it eliminates only the targets that are predicted not to have small molecular ligands even with low micromolar affinity. In view of the weak hot spots, ZipA, the TNFa/TNFR interface, and the first eight proteins in Table S9 represent such inherently non-druggable targets.
As shown in Table 1 , adjusting the side chains to account for their flexibility increased the number of probe clusters in 4 of the 7 druggable PPI targets with unbound X-ray (rather than NMR) structures, thus flexibility is important for 57% of cases. Based on Tables S2 and S8 , flexibility is important for 7 of the 20 (35%) druggable non-PPI targets, which agrees with the notion that PPI targets are more flexible than traditional drug targets.
The flexibility of side chains does not lead to druggability if there is no major hot spot in the binding site. In fact, accounting for flexibility we were able to open a pocket only in one (HI-0065) of the 9 non-druggable traditional drug targets (8 from Table S9 and cytochrome P450cam from Table S2 ), but even in HI-0065 the site did not meet our condition for druggability. In the interface, between Y87 and Q125 side chains 7(5) 7(2) Near the trifluoromethylphenyl and dimethyl chromone moieties of SP307 1 (36) Inside the core of the TNF-α trimer, near the trifluoromethylphenyl moiety of SP307 6(6) 4 (11) In the core, between dimethyl chromone and K98 3(19) In the core, between Y59 and Y151 2(14) In the core of the trimer, near S99, W114, E116 1(22)&4 ( For each side chains, Conformer 1 is very close to the unbound structure, and hence the only variations are switching to Conformer 2 one-by-one and then together. For F97 Conformer 2 has relatively high energy. There are no alternative conformers for F105, and Conformer 2 for V141 has low probability. More details on the calculation are given in SI Methods. 
Comment:
The maximum number of probe clusters bind when both R100 and Y101 are changed to Conformer 2. To measure the improvements in the quality of the mapping results due to accounting for side chain flexibility, we count the number of nonbonded interactions between the probes and each of the Bcl-xL residues, and compare the results to values obtained for the ligand-bound structure by calculating the correlation coefficient between the two vectors. As shown in Table S3 , the correlation coefficient increases from 0.51 to 0.92 as we adjust the two side chains. (42) of probe clusters is found for models 4, 19, and 23, but the best correlation (r=0.79) between unbound and bound fingerprints is reached for model 9, which has only 36 probe clusters. Nevertheless, the hot spots in any of the models with the maximum number of probe clusters (i.e., 4, 19, or 23) correctly show the druggability of this target. Fig. S1 . Small molecule inhibitors of the target proteins used in this study, with the PDB code of the protein/inhibitor complex given in parenthesis. 1 -Interleukin-2 (1pw6); 2 -Bcl-xL (2yxj); 3 -MDM2 (1rv1); 4 -HPV11 (1r6n); 5 -ZipA (1s1s); and 6 -TNFα (2az5). Table S3 ). Both side chains move toward their conformers in the bound Bcl-xL structure. R100 has many low energy conformers, with the highest probability one being close to the unbound. We selected the one with the second highest probability because it yields the highest number of probe clusters, which moves the conformation toward that of the bound. The RMSD between this predicted and the bound R100 conformers is 2.08 Å, but the mapping results become very similar to those obtained for the bound Bcl-xL structure.
R100
Y101 Fig. S3 . Mapping results for the unbound structure of HPV-11 E2 TAD (PDB code 1r6k). The two bound inhibitor molecules (from PDB code 1r6n) are superimposed for reference. CS1 (cyan, 18 clusters) is in the pocket which binds the indandione moiety of the high affinity inhibitor (inhibitor A, shown in green). Two more consensus sites are close to CS1: CS5 (grey, 11 clusters), which overlaps with the dichlorophenyl moiety of the low affinity inhibitor (inhibitor B, shown in magenta), and CS6 (blue, 10 clusters), located in a relatively shallow pocket close to residues Q12, L15, Y19, and E39, not reached by the inhibitors. In the ligand-bound structure this pocket contains an isobutyric acid, but CS6 does not completely overlap with the isobutyric acid position. We emphasize that the main hot spot CS1 is at the site binding the higher affinity inhibitor even when mapping the unbound structure. However, the correlation to the bound mapping results improves as we change to alternative side chain conformers (Tables S5 and S6) .
Fig. S4.
Mapping the TNFα structure from the co-crystal with compound 6 (PDB code 2az5). CS1 (cyan, 36) covers both the trifluoromethylphenyl indole and dimethyl chromone moieties of 6, CS2 (magenta, 14) almost perfectly overlaps with the phenyl ring of the indole moiety, and CS4 (salmon, 11) partially overlaps with the trifluoromethyl group. Fig. S5A . Mapping of the Bcl-xL structure from the complex co-crystallized with the Bak peptide (PDB code 1bxl). The inhibitor ABT-737 is superimposed for reference. The largest consensus site CS1 (cyan, 23 probe clusters), is in the pocket which binds the I85 side chain of the peptide and the thio-phenyl moiety of ABT-737. CS2 (magenta, 17 probe clusters) is in the pocket which binds L78 of the peptide and the chloro-biphenyl moiety on the other end of ABT-737. There are two more consensus sites in the Bcl-xL/peptide interface. CS4 (salmon, 13 clusters) is located a pocket which binds the V74 side chain of the peptide near the chloro-biphenyl binding region. Since the distal ring of the chloro-biphenyl group turns down toward the higher affinity bottom of the pocket, it does not reach this additional hot spot. CS5 (grey, 13 clusters) is in a pocket which binds the I81 side chain, but does not contribute to the binding of ABT-737.
Fig. S5B.
Mapping results for the structure of MDM2 co-crystallized with a 9 residue long peptide fragment of p53 (PDB code 1t4f), with the inhibitor Nutlin-2 (3) superimposed for reference. There are only two large consensus sites, both in the peptide binding region. CS1 (cyan, 38 probe clusters) is very large and occupies two pockets, the first binding W23 and the second L26 of the peptide. These same pockets bind the two bromophenyl groups of Nutlin-2. CS2 (magenta, 22 clusters) overlaps with the side chain of F19 of the peptide and the ethyl ether moiety of Nutlin-2. The remaining two consensus sites are much smaller, and far from the peptide binding site. Fig. S5C . Mapping of the ZipA structure, co-crystallized with the FtsZ peptide (PDB code 1f47). The largest consensus site in the interface region is CS5 (grey, 13 probe clusters) located in a pocket which binds the L372 side chain of the peptide and the sulfonamide moiety of the inhibitor. The next consensus site in the interface is CS6 (blue, 6 probe clusters), located in a shallow pocket which binds the F377 side chain of the peptide and the ring in the indole moiety of the inhibitor. Finally, there is a very small consensus site, CS7 (green, 3 clusters), overlapping with the I374 side chain of the peptide and the pyridine ring in the indoloquinolizinone. We note that CS2 (magenta, 17 probe clusters) is only at 5.2 Å from the indoloquinolizinone oxygen, and is located in a deep pocket surrounded by the side chains of Ser60, Phe85, Gln87, and Tyr 91. This hot spot does not overlap with the FtsZ peptide, but it might overlap with the extended FtsZ protein.
